The steep tariff on foreign-made drugs is an aggressive tactic to compel pharmaceutical companies to bring manufacturing back to the US. It aims to solve two critical problems: reducing strategic dependency on adversaries like China and rebuilding domestic manufacturing jobs.

The push for supply chain diversification and reduced reliance on China is not a new phenomenon. The COVID-19 pandemic first exposed the critical risks of single-source dependency. Recent tariff threats are not the origin of this strategic realignment but rather a powerful accelerant, forcing companies to act on plans already in motion.

The biopharma outsourcing sector has proven surprisingly resilient to international tariffs. Instead of absorbing costs, well-funded European companies are bypassing tariffs altogether by investing in and building new production facilities directly on U.S. soil, effectively onshoring their manufacturing.

Companies like Bridge Bio are publicly agreeing to the White House's 'Most Favored Nation' pricing while privately securing critical carve-outs. Bridge Bio obtained a forward-looking exclusion for orphan drugs, which covers its entire pipeline. This suggests companies are trading symbolic compliance for political goodwill while ensuring the deals have minimal financial impact.

The most crippling aspect of the ongoing tariff saga is the uncertainty it creates. The inability for businesses, especially small ones, to conduct long-term planning due to unpredictable policy shifts is more economically damaging than the direct financial cost of the duties.

The administration's proposed 100% tariffs on some pharma companies are more political posturing than substantive policy. The tariffs exclude generics, orphan drugs, and rare disease treatments. Additionally, 16 of the 17 largest pharma companies have already signed deals with the U.S., making them exempt.

The proposed pharma tariffs include a key loophole: the Secretary of Commerce can exempt any product by designating it a "specialty drug." This subjective clause opens the door for political influence, cronyism, and intense lobbying to secure exemptions, adding a layer of political risk for companies.

Unlike large firms making US investment pledges for exemptions, smaller drug makers must rely on nuanced, capital-light tactics. These include unbundling costs to lower dutiable value, using duty drawback programs for re-exported goods, and leveraging foreign trade zones to survive high tariff rates without massive infrastructure spending.

The proposed pharma tariffs exempt companies with MFN (Most Favored Nation) deals, which are primarily large players. This gives them a strategic advantage in M&A, as they can acquire smaller, tariff-burdened companies and absorb their assets into a tariff-free structure, creating favorable deal dynamics.